Dyadic International Azioni (NASDAQ: DYAI)

Ultime notizie per Dyadic International (NASDAQ:DYAI) Azioni

Dyadic International

Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

Dyadic International, Inc. - Common Stock

Dyadic International Inc

News

DYAI

Dyadic Receives $3M Grant From Gates Foundation For Cell Line Development Of Monoclonal Antibodies For RSV And Malaria Using C1 Platform Technology

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.07) by 85.71 percent. The company reported quarterly sales of $1.958 million which beat the analyst consensus estimate of $1.100 million by 78.00 percent. This is a 393.12 percent increase over sales of $397.060 thousand the same period last year.

Earnings

Earnings Beats

Dyadic International Q3 2024 GAAP EPS $(0.01) Beats $(0.07) Estimate, Sales $1.958M Beat $1.100M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is gearing up to announce its quarterly earnings on Tuesday, 2024-11-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Dyadic International will report an earnings per share (EPS) of $-0.06.
The market awaits Dyadic International's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 0.74% increase in the share price the following trading session.
Here's a look at Dyadic International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td></td>
<td>-0.06</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.07</td>
<td>-0.07</td>
<td>-0.08</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>5.0%</td>
<td>2.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Dyadic International were trading at $1.14 as of November 08. Over the last 52-week period, shares are down 34.13%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DYAI/earnings">To track all earnings releases for Dyadic International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Exploring Dyadic International's Earnings Expectations

Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company")&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>), a biotechnology company focused on the efficient, large-scale manufacture of proteins for use in non-pharmaceutical applications including food, nutrition and wellness, as well as animal and human health therapeutics and vaccines, today provided an update on business progress and announced its attendance at the Bioprocess International Conference in Boston, September 23-26, 2024.&nbsp;
At the conference, Dyadic will highlight its C1 and Dapibus&#x2122; microbial platforms, which are designed to improve the efficiency and lower the cost of manufacturing recombinant proteins such as:
<ul>
<li>Recombinant human albumin: for use in cell culture media, diagnostics, and as a stabilizing agent for vaccine production.</li>
<li>Bovine transferrin: for use in cell culture media and delivery of cancer therapeutics, among other uses.</li>
<li>Human lactoferrin: for use in research and pharmaceutical applications as potential antimicrobial, anti-inflammatory, and immune-supportive products.</li>
<li>Bovine alpha-lactalbumin: for use in products including infant formula, dietary supplements, and functional foods.</li>
</ul>
As the Company enters the fourth quarter, Dyadic continues to advance partnerships supported by the Dapibus&#x2122; platform targeted at the alternative protein market, seeking near-term recurring revenue growth while continuing to advance the C1 platform in the animal and human health markets.&nbsp;&nbsp;
Recent Developments in Alternative Proteins and Life Sciences:
<ul>
<li>Proliant Health and Biologicals ("PHB"), a leading manufacturer of proteins serving companies in microbiological, life sciences, biopharmaceutical, and veterinary sciences through its partnership with Dyadic, is expected to launch animal-free recombinant albumin in the first half of 2025 into the approximately $5B serum albumin market. Dyadic received $1 million in payments from PHB in Q3 and expects to receive additional payments after meeting certain productivity goals, and a share of profits from the sales of recombinant albumin products.</li>
<li>The development of Dyadic's DNase-I (deoxyribonuclease I) protein has been completed, and product sampling is ongoing.&nbsp;DNase-I is an enzyme that has several key potential applications across different industries, including pharmaceuticals, research, diagnostics, and therapeutic treatments.</li>
<li>Dyadic's project to produce recombinant bovine transferrin, used in cell culture media for the alternative protein market, has achieved high productivity, with further optimizations ongoing and application testing in cell culture media expected later this year.</li>
<li>The development of recombinant human lactoferrin is ongoing, which has potential applications in multiple pharmaceutical and non-pharmaceutical markets.</li>
<li>A project to produce recombinant bovine growth factor (FGF) is ongoing, with potential applications in cell culture, tissue engineering, stem cell research, and oncology. Initial results are expected in the fourth quarter. &nbsp;</li>
</ul>
Upcoming Conference: <a href="https://www.globenewswire.com/Tracker?data=eYK-uXcuTDoniXSsAhnDainP1ySQXjNT9W_RAynW3ZTAqHSFl8GE_zFc3yz4WHTfhqYvdz34a-v5RAQZ8Ex68XW-CYtHG-j2e6xl0QrtqIThm1rNhdaz7rdwssfBfOoJzFqPjfWVRoKOMRHn597zFnmxA5wtBxImWtMfaPpsOHVz8ifGvgakZJJV7D0rTiIAhL7F8moZeyM4vo_odXpFguZ54GhLgHZ9A4PoyBZgGIFfGN6jxWekSe_7HtZkoR8Jwqd9mcQGOEkQnLvtI-qLJfsu5JIBwTKd0qUN6ERZwDFfsS2SaVwEXAsuL9je84WL1CdpoOe9Hz1BF5JfMIHGQSRkjNyI9mW5f7NjHE2VZ3l-cjuSkygy_PoANrhUbuqEYcSTTbDJDnSI-linDsSqJ6sQzmVmuMSUb3WPaY9Ce3Oek_ZKQj1A_7_-CnMSYQuV">Bioprocess International 2024</a> Hynes Convention Center, Boston, USA September 23-26, 2024
If you would like to schedule a meeting with one of our management members at BPI, please contact Sam Closa at <a href="https://www.globenewswire.com/Tracker?data=mKatKPuW7z7zAQjSL0zJVdP7tGgv0GDGl_-tDh3AveGdeuDY2OhVmDM3e-C4ulXDJOF-oD5Fe8_goTkT43l3nA==">a</a><a href="https://www.globenewswire.com/Tracker?data=EDbZZBL-BBplsILt6uGrHpUL0Mglx6ux5dyzuiVKbWau8U7mgFYez7FEyXc8t7P5Qx3nm5DNcMIV8Un33ozbipgoNrkS11cqt-u0I9Mecl0=">ssistant@dyadic.com</a>.

Biotech

General

Dyadic Provides Update On Business Progress And Announces It Will Attend The Bioprocess International Conference In Boston, September 23-26, 2024

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $385.896 thousand which missed the analyst consensus estimate of $1.000 million by 61.41 percent. This is a 53.90 percent decrease over sales of $837.159 thousand the same period last year.

Earnings Misses

Dyadic International Q2 2024 GAAP EPS $(0.07), Inline, Sales $385.896K Miss $1.000M Estimate

<a href="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07012024_DYAI_Vandermosten.pdf" title="https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07012024_DYAI_Vandermosten.pdf">https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_07012024_DYAI_Vandermosten.pdf</a>

Trading Ideas

Watching Dyadic International; Zacks Small-Cap Research Gives Stock $9 Price Valuation

Dyadic International, Inc. ("Dyadic") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.
According to the terms of the agreement, Dyadic will receive an upfront milestone payment of $1.5MM and have agreed to a share of profits received by PHB from the sale of animal-free recombinant albumin products produced using Dyadic's filamentous fungal microbial platforms. A portion of the upfront milestone payment will be allocated to the technology transfer and commercialization effort. The initial focus of the partnership will be the commercialization of recombinant human serum albumin products, with the anticipated launch of the first product in the first half of 2025.

Contracts

Dyadic International And Proliant Health And Biologicals Announce Recombinant Albumin Development And Commercialization Partnership;  Dyadic Will Receive An Upfront Milestone Payment Of $1.5M

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) reported quarterly losses of $(0.07) per share. This is a 133.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $334.62 thousand in sales this quarter. This is a 65.79 percent decrease over sales of $978.05 thousand the same period last year.

Dyadic International Q1 EPS $(0.07) Down From $(0.03) YoY, Sales $334.62K Down From $978.05K YoY

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Dyadic International missed estimated earnings by -33.0%, reporting an EPS of $-0.08 versus an estimate of $-0.06.
Revenue was down $57 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 5.0% drop in the share price the next day.

To track all earnings releases for Dyadic International <a href="https://www.benzinga.com/quote/DYAI/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Dyadic International Q4 Earnings

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $686.53 thousand which missed the analyst consensus estimate of $800.00 thousand by 14.18 percent. This is a 7.69 percent decrease over sales of $743.73 thousand the same period last year.

Dyadic International Q4 EPS $(0.08) Misses $(0.06) Estimate, Sales $686.53K Miss $800.00K Estimate

Management

Dyadic International Appoints Patrick Lucy As Chairman; Succeeds Michael Tarnok  Effective Immediately

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

AFMD

AONC

AREC

ATAT

AXDX

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DARE

DLPN

DNMR

DOOO

DRIO

DTST

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Dyadic International will report an earnings per share (EPS) of $-0.06. 
Dyadic International bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 4.76% drop in the share price the next day.
Here's a look at Dyadic International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.05</td>
<td></td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.07</td>
<td>-0.03</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>10.0%</td>
<td>10.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>

<a href="https://www.benzinga.com/quote/DYAI/earnings">To track all earnings releases for Dyadic International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dyadic International's Earnings: A Preview

The first trial using a C1 produced monoclonal antibody provides equivalent protection against SARS-CoV-2 in hamster and nonhuman primate models compared to monoclonal antibody produced in CHO.

Dyadic Publishes C1 Monoclonal Antibody In Nonhuman Primate Study In Nature Communications

<h3>Gainers</h3>
<ul>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) shares increased by 74.5% to $1.85 during Monday's pre-market session. The company's market cap stands at $4.4 million. </li>
<li>Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) stock rose 21.73% to $1.68. The company's market cap stands at $48.4 million. </li>
<li>Mesoblast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) shares rose 19.53% to $2.57. The company's market cap stands at $260.8 million. </li>
<li>Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) stock moved upwards by 15.28% to $8.22. The market value of their outstanding shares is at $30.7 million. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) stock increased by 13.77% to $1.28. The market value of their outstanding shares is at $21.7 million. The company's, Q4 earnings came out 3 days ago. </li>
<li>Graphite Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPH#NASDAQ">GRPH</a>) stock rose 12.1% to $3.52. The company's market cap stands at $204.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) shares fell 15.6% to $1.73 during Monday's pre-market session. The company's market cap stands at $8.0 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares decreased by 11.64% to $0.43. The market value of their outstanding shares is at $3.1 million. </li>
<li>Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) shares fell 10.32% to $33.03. The market value of their outstanding shares is at $2.9 billion. As per the press release, Q4 earnings came out today. </li>
<li>Avenue Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXI#NASDAQ">ATXI</a>) stock fell 9.64% to $0.17. The company's market cap stands at $6.4 million. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) stock fell 9.31% to $1.95. The market value of their outstanding shares is at $16.3 million. </li>
<li>Yield10 Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTEN#NASDAQ">YTEN</a>) shares fell 7.69% to $0.25. The company's market cap stands at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIMD

APRE

ATXI

FTRE

GRPH

INDP

MESO

TCBP

TLPH

YTEN

12 Health Care Stocks Moving In Monday's Pre-Market Session

Dyadic International, Inc. ("Dyadic",&nbsp;"we",&nbsp;"us",&nbsp;"our", or the&nbsp;"Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health today announced its Dutch subsidiary, Dyadic Nederland BV has entered into a strategic partnership agreement and collaboration with Rabian BV ("Rabian"), a Dutch innovative SME founded by experienced entrepreneurs and vaccine scientists. The aim is to develop highly efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform. This collaboration seeks to address the global burden of rabies, a disease that annually claims tens of thousands of lives. &nbsp;
Awarded by Eurostars for the AVATAR project, a part of the European Partnership on Innovative SMEs, and co-funded by the European Union through Horizon Europe. Rabian will use the total funding of approximately Є 1.7 million leveraging its expertise in virology to develop a rabies vaccine using Dyadic's C1 protein production platform to tackle the challenges posed by rabies, particularly in lower- and middle-income countries. As per the strategic partnership agreement, Dyadic will receive an equity stake in, fully funded research and development costs, and specified product milestones and royalties upon commercialization.
Mark Emalfarb, Dyadic's Chief Executive Officer, commented, "I am excited to be able to continue our long relationship with Rabian's scientists in their mission to provide affordable vaccines and prophylactics for Lower- and Middle-Income Countries (LMIC), as well as to expand potential opportunities for human health commercial traveler products using Dyadic's proprietary C1 platform. Rabies kills thousands each year and we welcome the opportunity to address this terrible human health issue with such a capable partner".
Drs. Carine Punt, CEO of Rabian, emphasized the extensive collaboration between Rabian's scientists and Dyadic spanning nearly a decade with projects such as the EU-funded Zoonosis Anticipation Preparedness Initiative (ZAPI) and pre-clinical vaccine development for diseases like rabies and COVID-19. Drs. Punt highlighted the potential of combining advances in vaccinology with Dyadic's C1 protein production platform to accelerate research, enhance product development, and lower manufacturing costs.
Drs. Punt underscored the ongoing threat of rabies to human lives, especially in resource-poor communities, and emphasized the importance of making preventive vaccination more widely available, particularly for travelers to endemic areas. Despite the availability of preventive vaccination and post-exposure treatment, rabies continues to claim thousands of lives annually, with the highest incidence in LMICs. Drs. Punt highlighted the need for concerted efforts to combat rabies and ensure its prevention through accessible and cost-effective vaccination strategies.
About Rabian BV
Rabian BV is an innovative Dutch SME in the field of infectious diseases, founded in 2023 by a multi-disciplinary team of seasoned entrepreneurs and world-leading scientists with a broad background in immunology, virology, and commercialization. It is our mission to develop cost-effective vaccines and post-exposure treatments of diseases with endemic and pandemic potential. Rabian aims to become a leading developer of cost-effective vaccine and prophylactic therapies of endemic infectious diseases.

Dyadic Announces Strategic Partnership Agreement To Develop Affordable Rabies Prophylactics And Vaccines Using Its C1 Cell Microbial Protein Production Platform

Dyadic Advances Collaboration With Israel Institute For Biological Research Targeting Bio-Threats And Emerging Disease Solutions

An announcement from Dyadic International (DYAI) is now available. Dyadic International, Inc. has struck a deal with Proliant Health and Biological...

Dyadic International Secures Lucrative Biotech Licensing Deal

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Dyadic International (DYAI – Research Report), with a...

Dyadic International: A Buy Rating on Strong Partnership Prospects and Revenue Growth Potential

Dyadic International GAAP EPS of -$0.07 in-line, revenue of $385.89M beats by $384.89M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Dyadic International (NASDAQ:<a href="https://investorplace.com/stock-quotes/dyai-stock-quote/">DYAI</a>) just reported results for the second quarter of 2024.<ul><li>Dyadic International reported earnings per share of -7 cents. This was below the analyst estimate for EPS of -6 cents.</li><li>The company reported revenue of $385,896.</li><li>This was 61.41% worse than the analyst estimate for revenue of $1.00 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/dyai-stock-earnings-dyadic-international-for-q2-of-2024/">DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

DYAI Stock Earnings: Dyadic International Misses EPS, Misses Revenue for Q2 2024

Comments

Dyadic International

Notizie

Ultime notizie per Dyadic International (NASDAQ:DYAI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO